Praxis Precision Medicines annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Praxis Precision Medicines Free Cash Flow (FCF) History (PRAX)
Praxis Precision Medicines reported −$249.1M in free cash flow for fiscal 2025, a decrease of $117.4M from the previous fiscal year.
View full Praxis Precision Medicines company overviewPraxis Precision Medicines free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$249.1M | −$117.4M | — | — |
| 2024 | 2024-12-31 | −$131.8M | −$20.6M | — | −1540.48% |
| 2023 | 2023-12-31 | −$111.2M | $74.3M | — | −4543.77% |
| 2022 | 2022-12-31 | −$185.5M | −$59.9M | — | — |
| 2021 | 2021-12-31 | −$125.6M | −$73.0M | — | — |
| 2020 | 2020-12-31 | −$52.6M | −$19.1M | — | — |
| 2019 | 2019-12-31 | −$33.5M | — | — | — |
Praxis Precision Medicines quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$77.8M | −$23.1M | — | — |
| Q1 2026 | 2026-03-31 | −$86.2M | −$33.2M | — | — |
| Q4 2025 | 2025-12-31 | −$76.3M | −$48.8M | — | — |
| Q3 2025 | 2025-09-30 | −$65.1M | −$41.1M | — | — |
| Q2 2025 | 2025-06-30 | −$54.7M | −$31.5M | — | — |
| Q1 2025 | 2025-03-31 | −$53.0M | −$21.8M | — | — |
| Q3 2024 | 2024-09-30 | −$27.5M | $5.3M | — | −9105.96% |
| Q4 2023 | 2023-12-31 | −$23.9M | $4.9M | — | −4642.91% |
| Q3 2023 | 2023-09-30 | −$23.2M | $21.7M | — | −4960.47% |
| Q2 2023 | 2023-06-30 | −$31.2M | $26.1M | — | −3996.67% |
| Q1 2023 | 2023-03-31 | −$32.8M | $21.6M | — | −4809.08% |
| Q4 2022 | 2022-12-31 | −$28.8M | $16.6M | — | — |
| Q3 2022 | 2022-09-30 | −$45.0M | −$20.6M | — | — |
| Q2 2022 | 2022-06-30 | −$57.3M | −$27.2M | — | — |
| Q1 2022 | 2022-03-31 | −$54.4M | −$28.7M | — | — |
| Q4 2021 | 2021-12-31 | −$45.4M | −$25.2M | — | — |
| Q3 2021 | 2021-09-30 | −$24.4M | −$10.5M | — | — |
| Q2 2021 | 2021-06-30 | −$30.1M | −$20.1M | — | — |
| Q1 2021 | 2021-03-31 | −$25.7M | −$17.2M | — | — |
| Q4 2020 | 2020-12-31 | −$20.2M | — | — | — |
| Q3 2020 | 2020-09-30 | −$13.9M | — | — | — |
| Q2 2020 | 2020-06-30 | −$9.9M | — | — | — |
| Q1 2020 | 2020-03-31 | −$8.6M | — | — | — |
Praxis Precision Medicines free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$52.6M to −$249.1M, a net decrease of $196.5M. Praxis Precision Medicines's latest reported quarter, Q2 2026, generated −$77.8M in free cash flow, a decrease of $23.1M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Praxis Precision Medicines filings at SEC.gov ↗